675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Announces First Quarter 2026 Operating Results and Provides Business Update
Annual Report to Security Holders
Financial Results, Press Release
Material disclosure
GSK Files NDA Resubmission for Tebipenem HBr; $25M Milestone Payment Triggered
Announces Third Quarter 2025 Operating Results and Provides a Business Update
Announces Second Quarter 2025 Operating Results and Provides a Business Update
Q1
Q3
Q2
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence
Confidential Treatment Order